Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 4,801–4,900 of 10,906
Branche, A. R., Mulligan, M. J., Maniar, A., Puente, O. A., Oladipupo, I., Crowther, G., Zareba, A., Yi, Z., Scully, I. L., Gomme, E. A., et al. (2025) · Vaccines · doi:10.3390/vaccines13040383 · Cited by 12
“Of note, two safe and efficacious lipid nanoparticle-encapsulated modRNA vaccines encoding the SARS-CoV-2 spike protein were developed and successfully deployed in response to the global public health emergency presented by the COVID-19 pandemic [14,15].”
(2021) · doi:10.1101/2021.03.05.21252590 · Cited by 139
Pai, M., Tung, K., Hsu, S., Peng, Y., Lin, W., Yang, J., Wu, H., Chiu, Y., Shu, K.-H., & Tsai, W. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2172432 · Cited by 9
COVID-19 vaccines in high-risk ethnic groups
D’Souza, R., & Wolfe, I. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00624-3 · Cited by 11
Preparation of targeted lipid nanoparticles for precision nucleic acid delivery
Geisler, H. C., Battistini, E., Thatte, A. S., Padilla, M. S., & Mitchell, M. J. (2026) · Nature Protocols · doi:10.1038/s41596-025-01330-w · Cited by 24
Sidlow, J. S., Reichel, M., & Lowenstein, E. J. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.05.018 · Cited by 11
Inshasi, J. S. S., Alroughani, R., Al-Asmi, A. R., Al-Khabouri, J., Alsalti, A., Boshra, A., Canibaño, B., Deleu, D., Ahmed, S. F., Shatila, A. O., et al. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00260-5 · Cited by 11
Progress in antisenescence biomaterials for improved osteoarthritis therapy
Ge, Y.-S., Ding, J.-Y., Shen, J., Meng, T.-T., Huang, C.-M., Li, W.-Y., Zhao, M.-J., Yin, J.-L., Zhai, Y.-Q., Wang, X., et al. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.08.044 · Cited by 15
Arashiro, T., Miwa, M., Nakagawa, H., Takamatsu, J., Oba, K., Fujimi, S., Kikuchi, H., Iwasawa, T., Kanbe, F., Oyama, K., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2023.12.033 · Cited by 11
Rzymski, P., Sikora, D., Zeyland, J., Poniedziałek, B., Kiedik, D., Falfushynska, H., & Fal, A. (2022) · Vaccines · doi:10.3390/vaccines10050754 · Cited by 12
Structure of a SARS-CoV-2 spike S2 subunit in a pre-fusion, open conformation
Olmedillas, E., Rajamanickam, R. R., Avalos, R. D., Ana-Sosa-Batiz, F., Zyla, D., Zandonatti, M. A., Harkins, S. S., Shresta, S., Hastie, K. M., & Saphire, E. O. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116052 · Cited by 19
Beaudoin-Bussières, G., Chen, Y.-Z., Ullah, I., Prévost, J., Tolbert, W., Symmes, K., Ding, S.-L., Benlarbi, M., Gong, S., Tauzin, A., et al. (2021) · bioRxiv · doi:10.1101/2021.09.08.459408 · Cited by 15
Gilbert, J., Ermilova, I., Fornasier, M., Skoda, M., Fragneto, G., Swenson, J., & Nylander, T. (2023) · Nanoscale · doi:10.1039/d3nr03308b · Cited by 12
Aznar-Gimeno, R., Paño‐Pardo, J. R., Esteban, L. M., Labata-Lezaun, G., Esquillor-Rodrigo, M. J., Lanas, Á., Abadía, D., Díez‐Fuertes, F., Tellería, C., Alonso, R. D. H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98308-x · Cited by 10
Sentinel cells enable genetic detection of SARS-CoV-2 Spike proteinPreprint
Weinberg, Z. Y., Hilburger, C. E., Kim, M. J., Cao, L., Khalid, M. M., Elmes, S., Diwanji, D. C., Hernandez, E., Lopez, J., Schaefer, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.20.440678 · Cited by 12
Cardiac Fibroblasts: Helping or Hurting
Shameem, M., Olson, S. L., de Velasco, E. M. F., Kumar, A., & Singh, B. N. (2025) · Genes · doi:10.3390/genes16040381 · Cited by 16
“Other studies have targeted signaling pathways to block the activation of CFs, such as a blockade of TGF-β signaling using small molecule inhibitors or an antibody-mediated blockade of BMP-signaling which led to the reduction in fibrosis and improved cardiac function [55].”
Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients
Romano, E., Pascolo, S., & Ott, P. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002932 · Cited by 11
Sodium Toxicity in the Nutritional Epidemiology and Nutritional Immunology of COVID-19
Brown, R. B. (2021) · Medicina · doi:10.3390/medicina57080739 · Cited by 11
Intranasal booster induces durable mucosal immunity against SARS-CoV-2 in mice
Mukesh, R. K., Hill, T., Kaiser, F. K., Prado-Smith, J., Schulz, J. E., Gallogly, S., Herbold, L., Bauer, K., Smith, B. J., Myers, L. M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-06880-3 · Cited by 13
Humoral Responses Elicited after a Fifth Dose of SARS-CoV-2 mRNA Bivalent Vaccine
Tauzin, A., Beaudoin-Bussières, G., Benlarbi, M., Nayrac, M., Bo, Y., Gendron‐Lepage, G., Medjahed, H., Perreault, J., Gokool, L., Arlotto, P., et al. (2023) · Viruses · doi:10.3390/v15091926 · Cited by 11
Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases
Córdoba, K. M., Jericó, D., Sampedro, A., Jiang, L., Iraburu, M. J., Martini, P. G. V., Berraondo, P., Avila, M. A., & Fontanellas, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.03.005 · Cited by 14
Harnessing the Loop: The Perspective of Circular RNA in Modern Therapeutics
Zhao, Y.-Y., Zhu, F.-M., Zhang, Y.-J., & Wei, H. Y. (2025) · Vaccines · doi:10.3390/vaccines13080821 · Cited by 20
Blanquart, F., Abad, C., Ambroise, J., Bernard, M., Débarre, F., Giannoli, J., Rey, T., & Vieillefond, V. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.04.410 · Cited by 13
Obel, N., Fox, M. P., Tetens, M. M., Pedersen, L. H., Krause, T. G., Ullum, H., & Sørensen, H. T. (2024) · Clinical Epidemiology · doi:10.2147/clep.s468572 · Cited by 13
Guo, Y., Cao, X., Yang, H.-T., Zhou, M., & Yu, B. (2023) · Journal of Global Health · doi:10.7189/jogh.13.06008 · Cited by 13
Natalini, A., Simonetti, S., Sher, C., D’Oro, U., Hayday, A., & Rosa, F. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214367 · Cited by 15
Testa, S., Haabeth, O. A. W., Blake, T. R., Castillo, T. J. D., Czerwinski, D. K., Rajapaksa, R., Wender, P. A., Waymouth, R. M., & Levy, R. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00469 · Cited by 11
Yuniar, C. T., Pratiwi, B., Ihsan, A. F., Laksono, B. T., Risfayanti, I., Fathadina, A., Jeong, Y., & Kim, E. Y. (2022) · Vaccines · doi:10.3390/vaccines10020313 · Cited by 16
Hagiya, H., Nakano, Y., Furukawa, M., Sunada, N., Hasegawa, T., Sakurada, Y., Hasegawa, K., Yamamoto, K., Ogawa, H., Obara, T., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24464-3 · Cited by 13
Arāja, D., Krūmiņa, A., Nora-Krūkle, Z., Berķis, U., & Murovska, M. (2022) · Vaccines · doi:10.3390/vaccines10122115 · Cited by 11
Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
Asdaq, S. M. B., Jomah, S., Rabbani, S. I., Alamri, A. M., Alshammari, S. K. S., Duwaidi, B. S., Al-Shammari, M., Alamri, A. S., Alsanie, W. F., Alhomrani, M., et al. (2022) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2022/6913772 · Cited by 13
Cationic and Biocompatible Polymer/Lipid Nanoparticles as Immunoadjuvants
Pérez-Betancourt, Y., Araújo, P. M., Távora, B. D. C. L. F., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111859 · Cited by 11
The changing health impact of vaccines in the COVID-19 pandemic: A modeling study
Cohen, J. A., Stuart, R. M., Panovska‐Griffiths, J., Mudimu, E., Abeysuriya, R., Kerr, C. C., Famulare, M., & Klein, D. J. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112308 · Cited by 14
New insights for the development of efficient DNA vaccines
Berger, S., Zeyn, Y., Wagner, E., & Bros, M. (2024) · Microbial Biotechnology · doi:10.1111/1751-7915.70053 · Cited by 17
Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused
Gentile, I., Maraolo, A. E., Buonomo, A. R., Nobile, M., Piscitelli, P., Miani, A., & Moriello, N. S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111159 · Cited by 10
Kumari, A., Kumari, S., Kujur, M., Tirkey, S., & Singh, S. B. (2022) · Cureus · doi:10.7759/cureus.30682 · Cited by 12
Lin, Y.-H., Huang, H., & Hwang, W.-Z. (2022) · Medicine · doi:10.1097/md.0000000000028756 · Cited by 13
The Physiologic Response to COVID-19 Vaccination
(2021) · doi:10.1101/2021.05.03.21256482 · Cited by 11
Kelsen, S. G., Braverman, A. S., Aksoy, M. O., Hayman, J. A., Patel, P. S., Rajput, C., Zhao, H., Fisher, S. G., Ruggieri, M. R., & Gentile, N. (2022) · JCI Insight · doi:10.1172/jci.insight.155889 · Cited by 13
Su, N., Wiefels, C., Klein, R., et al. (2022) · Journal of medical imaging and radiation sciences · doi:10.1016/j.jmir.2022.01.004 · Cited by 11
Serological response to COVID-19 vaccination in IBD patients receiving biologicsPreprint
Wong, S.-Y., Dixon, R. E., Pazos, V. M., ICARUS-IBD Working Group, Gnjatic, S., Colombel, J., & Cadwell, K. (2021) · medRxiv · doi:10.1101/2021.03.17.21253848 · Cited by 11
Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines
Albalawi, O. M., Alomran, M. I., Alsagri, G. M., Althunian, T. A., & Alshammari, T. M. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.12.008 · Cited by 12
Innovative design of bacterial outer membrane vesicles for vaccine development
Cheng, Q., Niu, G., He, Y., Zhu, Y., Kang, Y., Zhang, Z., & Ji, X. (2025) · Nano Today · doi:10.1016/j.nantod.2025.102650 · Cited by 12
Wei, Z., Zhang, S., Wang, X., Xue, Y., Dang, S., & Zhai, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1524317 · Cited by 25
Kuitunen, I., Uimonen, M., Seppälä, S., & Ponkilainen, V. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12993 · Cited by 10
Impact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 dynamics in SwitzerlandPreprint
Shattock, A. J., Rutte, E. A. L., Dünner, R. P., Sen, S., Kelly, S. L., Chitnis, N., & Penny, M. A. (2021) · medRxiv · doi:10.1101/2021.04.14.21255503 · Cited by 11
Gulati, G. K., Simpson, A., MacMillen, Z., Krieger, K., Sharma, S., Erasmus, J. H., Reed, S. G., Davie, J. W., Avril, M., & Khandhar, A. P. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.023 · Cited by 14
Duarte, M. B. O., Leal, F. R. P., Argenton, J. L. P., et al. (2021) · Infectious Agents and Cancer · doi:10.1186/s13027-021-00406-y · Cited by 11
Mwimanzi, F., Lapointe, H., Cheung, P. K., Sang, Y., Yaseen, F., Umviligihozo, G., Kalikawe, R., Datwani, S., Omondi, F. H., Burns, L., et al. (2022) · medRxiv · doi:10.1101/2022.01.06.22268745 · Cited by 24
Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia
Pfrepper, C., Holstein, K., Königs, C., Heller, C., Krause, M., Olivieri, M., Bidlingmaier, C., Sigl-Kraetzig, M., Wendisch, J., Halimeh, S., et al. (2021) · Hämostaseologie · doi:10.1055/a-1401-2691 · Cited by 11
mRNA-Based Anti-TCR CDR3 Tumour Vaccine for T-Cell Lymphoma
Tusup, M., Läuchli, S., Jarzębska, N. T., French, L. E., Chang, Y., Eisenring, M., Su, A. A. H., Kündig, T. M., Guenova, E., & Pascolo, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071040 · Cited by 13
Scoccianti, S., Paoli, C. D., Leonulli, B. G., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00427-7 · Cited by 11
Návar, A. M., McNally, E. M., Yancy, C. W., O’Gara, P. T., & Bonow, R. O. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2853 · Cited by 12
Tang, G., Westover, K. D., & Jiang, S. B. (2021) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2021.666599 · Cited by 11
An mRNA vaccine encoding proteasome-targeted antigen enhances CD8+ T cell immunity
Ling, J., Chen, H., Huang, M., Wang, J., & Du, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.074 · Cited by 13
Building the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions
Link‐Gelles, R., Britton, A., & Fleming-Dutra, K. E. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.12.002 · Cited by 15
Kim, M., Kang, G., Min, H. S., Lee, Y., Park, S., & Jung, H. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2422939 · Cited by 11
Gonzalez‐Garcia, P., Muñoz-Miranda, J. P., Fernández-Cisnal, R., Olvera-Collantes, L., Moares, N., Gabucio, A., Fernandez-Ponce, C. M., & Garcia-Cozar, F. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087641 · Cited by 12
Biodegradable Polyester Nanoparticle Vaccines Deliver Self‐Amplifying mRNA in Mice at Low Doses
Wilson, D. R., Tzeng, S. Y., Rui, Y., Neshat, S. Y., Conge, M., Luly, K. M., Wang, E. B., Firestone, J. L., McAuliffe, J., Maruggi, G., et al. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202200219 · Cited by 13
Lessons from SARS‑CoV‑2 and its variants (Review)
Qin, Z., Sun, Y., Zhang, J., Zhou, L., Chen, Y., & Huang, C. (2022) · Molecular Medicine Reports · doi:10.3892/mmr.2022.12779 · Cited by 11
Dubé, C., Paris‐Robidas, S., Andreani, G., Gutzeit, C., D’Aoust, M., Ward, B. J., & Trépanier, S. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.046 · Cited by 13
Teeyapun, N., Luangdilok, S., Pakvisal, N., Sainamthip, P., Mingmalairak, S., Poovorawan, N., Sitthideatphaiboon, P., Parinyanitikul, N., Sriuranpong, V., Namkanisorn, T., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101608 · Cited by 11
MicroRNAs and Extracellular Vesicles in Milk: RNA-Based Micronutrients?
Cione, E., Zambrini, A. V., & Cannataro, R. (2021) · Journal of Nutrition · doi:10.1093/jn/nxab134 · Cited by 11
SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at Diagnosis
Alves, I., Vicente, M. M., Gaifem, J., Fernandes, Â., Dias, A. M., Rodrigues, C. S., Oliveira, J. C., Seixas, N., Malheiro, L., Abreu, M. A., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100131 · Cited by 11
Matsuura, R., Kawamura, A., Matsumoto, Y., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10091796 · Cited by 11
Tong, T., D’Addabbo, A., Xu, J., Chawla, H., Nguyen, A., Ochoa, P., Crispin, M., & Binley, J. Μ. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011452 · Cited by 12
Wang, S., Cui, H. Y., Zhang, C., Li, W., Wang, W., He, W., Feng, N., Zhao, Y., Wang, T., Tang, X., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105765 · Cited by 11
Shaharyar, M. A., Bhowmik, R., Al-Abbasi, F. A., AlGhamdi, S. A., Alghamdi, A. M., Sarkar, A., Kazmi, I. A., & Karmakar, S. (2023) · Vaccines · doi:10.3390/vaccines11020241 · Cited by 12
Engineering Hybrid Extracellular Vesicles for Functional mRNA Delivery
Louro, A. F., Gomes, I., Lu, C., Alfonzo‐Méndez, M. A., Dekker, N., Khan, M., & Lázaro‐Ibáñez, E. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202509636 · Cited by 14
Vaccines and nephrotic syndrome: efficacy and safety
Angeletti, A., Lugani, F., Porta, E. L., Verrina, E. E., Caridi, G., & Ghiggeri, G. M. (2022) · Pediatric Nephrology · doi:10.1007/s00467-022-05835-4 · Cited by 15
Søndergaard, M. H., Thavarajah, J. J., Henson, H. C., & Wejse, C. M. (2023) · HIV Medicine · doi:10.1111/hiv.13537 · Cited by 13
Wang, T. L., Krishnamurti, T., Bernard, M., Lopa, S., Quinn, B., & Simhan, H. N. (2022) · Behavioral Medicine · doi:10.1080/08964289.2021.2023456 · Cited by 10
Is a single COVID-19 vaccine dose enough in convalescents ?
Focosi, D., Baj, A., & Maggi, F. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1917238 · Cited by 13
van der Boom, M. D. X., van Eekeren, R., & van Hunsel, F. P. A. M. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5610 · Cited by 11
Lipid Nanoparticles for mRNA Delivery in Cancer Immunotherapy
Alshehry, Y., Liu, X., Li, W., Wang, Q., Cole, J., & Zhu, G. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01051-8 · Cited by 19
“Among these delivery systems, lipid-based nanocarriers, especially LNPs, have shown great potential for mRNA delivery thus far (29, 30), as evidenced by the US FDA approval of LNPs of small interfering RNA (siRNA) (Onpattro) (31) and mRNA-LNP COVID-19 vaccines (e.g., Comirnaty (32) and Spikevax (33)).”
COVID-19 pneumonia: lessons learned, challenges, and preparing for the future
Ufuk, F., & Savaş, R. (2022) · Diagnostic and Interventional Radiology · doi:10.5152/dir.2022.221881 · Cited by 11
Recent advances in the application of polymeric nanoparticles to the pulmonary delivery of mRNA
Panovich, P. M., Ganesan, A., Angadi, A. R., & Piotrowski-Daspit, A. S. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2509477 · Cited by 15
“For example, it was not until the SARS-COV-2 pandemic that mRNA vaccines received widespread acknowledgment and utilization [3–6].”
Onn, P., & Chang, C. L. (2021) · Respirology Case Reports · doi:10.1002/rcr2.860 · Cited by 11
The dynamics of quantitative SARS‐CoV‐2 antispike IgG response to BNT162b2 vaccination
Kaneko, S., Kurosaki, M., Sugiyama, T., Takahashi, Y., Yamaguchi, Y., Nagasawa, M., & Izumi, N. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27231 · Cited by 10
Watkins, L. F., Mitruka, K., Dorough, L., Bressler, S. S., Kugeler, K. J., Sadigh, K. S., Birhane, M. G., Nolen, L. D., & Fischer, M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac066 · Cited by 11
Lucca, F., Bezzerri, V., Danese, E., Olioso, D., Peserico, D., Boni, C., Cucchetto, G., Montagnana, M., Tridello, G., Meneghelli, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020908 · Cited by 12
Cai, G., Liu, S., Lu, Y., Takaki, Y., Matsumoto, F., Yoshikawa, A., Taguri, T., Xie, J., Arima, K., Mizukami, S., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2322795 · Cited by 13
Cegolon, L., Mastrangelo, G., Bellizzi, S., Filon, F. L., & Salata, C. (2023) · Pathogens · doi:10.3390/pathogens12020211 · Cited by 12
León, T. M., Vargo, J., Pan, E., Jain, S., & Shete, P. B. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab415 · Cited by 12
Lawal, B., Kuo, Y.-C., Sumitra, M. R., Wu, A. T. H., & Huang, H. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105814 · Cited by 13
COVID-19 Vaccination Hesitancy among Youths in Soweto, South Africa
Muthoni, J., Otwombe, K. N., Thaele, D., Choge, I., Steenberg, B., Cutland, C., Madhi, S. A., Sokani, A., & Myburgh, N. (2023) · Vaccines · doi:10.3390/vaccines11050960 · Cited by 11
Aviña, A. E., Paz, D. D., Huang, S.-C., Chen, K., Chang, Y., Lee, C.-M., Lin, C.-H., Wei, F., & Wang, A. Y. L. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.02.016 · Cited by 14
Haimei, M. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211040110 · Cited by 12
A comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort studyPreprint
Anscombe, C., Lissauer, S., Thole, H., Rylance, J., Dula, D., Menyere, M., Kutambe, B., van der Veer, C., Phiri, T., Banda, N. P., et al. (2022) · medRxiv · doi:10.1101/2022.02.17.22269742 · Cited by 15
Durable immune responses after BNT162b2 vaccination in home-dwelling old adults
Hansen, L., Brokstad, K. A., Bansal, A., Zhou, F., Bredholt, G., Onyango, T. B., Sandnes, H. H., Elyanow, R., Madsen, A., Trieu, M.-C., et al. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100262 · Cited by 15
Bauernfeind, S., Huppertz, G., Mueller, K., Hitzenbichler, F., Hardmann, L., Pemmerl, S., Hollnberger, H., Sieber, W., Wettstein, M., Seeliger, S., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac203 · Cited by 11
Jiménez, M., Fernández‐Naval, C., Navarro, V., Jáuregui, S. N., Martínez‐Gallo, M., Medina-Gil, D., Andrés, C., Antón, A., Peralta, S., Pujadas, G., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26951 · Cited by 13
Fischer, C., Willscher, E., Paschold, L., Gottschick, C., Klee, B., Diexer, S., Bosurgi, L., Dutzmann, J., Sedding, D., Frese, T., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00815-1 · Cited by 13
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.